Menu Search
Equities

BioDlink International Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1875:HKG.HZ

BioDlink International Co Ltd

Actions
  • Price (HKD)4.20
  • Today's Change0.00 / 0.00%
  • Shares traded250.00k
  • 1 Year change+133.33%
  • Beta0.2505
Data delayed at least 15 minutes, as of Feb 16 2026 03:45 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BioDlink International Co Ltd, formerly TOT BIOPHARM International Co Ltd, is a clinical-stage biopharmaceutical company principally engaged in developing and commercializing oncology drugs and therapies. The Company and its subsidiaries are primarily engaged in research, development, manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO) business and license-out of self-developed biological drugs in the People’s Republic of China. The Company owns a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The Company has built and established a fully integrated in-house platform of discovery, process development, quality management, pre-clinical and clinical development, as well as commercial-scale manufacturing facilities and sales and marketing capabilities. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)1.21bn
  • Net income in HKD8.22m
  • Incorporated2009
  • Employees604.00
  • Location
    BioDlink International Co Ltd120 Changyang StreetSuzhou Industrial ParkSuzhou 215024ChinaCHN
  • Phone+86 51 262965186
  • Fax+86 51 262965286
  • Websitehttps://www.biodlink.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.